Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT01704716

High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)

Conditions: Neuroblastoma

Sex: All
Ages: 1 Month – 21 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 3569
Sponsor: St. Anna Kinderkrebsforschung

Location: The John Hunter Children's Hospital Newcastle

Summary

This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis).The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba ® without s.c. aldesleukin (IL-2)). Last randomisation question (R4) was closed in March 2018. Since then all HRNBL1 patients are being registered and treated according SIOPEN standard recommendation as defined in protocol v1.8. For these patients the use of ch14.18/CHO antibody is recommended without scIL-2 as continuous infusion as standard of care outside of controlled trials. ch14.18/CHO received marketing authorization by EMA in May 2017 (Qarziba ®).In the induction phase, all patients receive Rapid COJEC following the result of the R3 randomization which was closed on June 8th, 2017 after inclusion of 630 patients as planned. Following induction treatment peripheral blood stem cell harvest (PBSCH) is performed and complete excision of the primary tumour will be attempted. Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles. After Rapid COJEC induction, localized patients will proceed to consolidation. Patients aged 12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and surgery to the primary tumour.Consolidation consists of BuMel MAT based on the results of the R1 randomization followed by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary tumour. With amendment 1.9 the End of recruitment was prolonged to Q2 2023 followed by a 5-year patient follow-up period.

Eligibility Criteria

Inclusion Criteria: * • Established diagnosis of neuroblastoma according to the International Neuroblastoma Staging System (INSS). * Age below 21 years. * High risk neuroblastoma defined as either: 1. INSS stage 2, 3, 4, and 4s with MYCN amplification, or 2. INSS stage 4 without MYCN amplification aged \> 12 months at diagnosis * Patients who have received no previous chemotherapy except for one cycle of etoposide and carboplatin (VP16/Carbo). In this situation patients will receive Rapid COJEC induction and the first Rapid COJEC cycle may be replaced by the first cycle VP16/Carbo (etoposide / carboplatin). * Written informed consent, including agreement of parents or legal guardian for minors, to enter a randomised study if the criteria for randomisation are met. * Tumour cell material available for determination of biological prognostic factors. * Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding. * Registration of all eligibility criteria with the data centre within 6 weeks from diagnosis. * Provisional follow up of 5 years. * National and local ethical committee approval. Exclusion Criteria: Any negative answer concerning the inclusion criteria of the study \-

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT01704716). StuddyBuddy aggregates publicly available trial information.